AbbVie Inc. — ABBV
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $219.16 | $387.34B | 167.3 | 18.1 | 36.6% | 10.2% | $6.92 3.2% | -146.6 |
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2021-12-31 | $56.2B | $11.5B | $6.53 | N/A | N/A | N/A |
| 1 | 2022-12-31 | $58.1B | $11.8B | $6.69 | 3.3% | 2.5% | 2.5% |
| 2 | 2023-12-31 | $54.3B | $4.9B | $2.75 | -6.4% | -58.9% | -58.8% |
| 3 | 2024-12-31 | $56.3B | $4.3B | $2.40 | 3.7% | -12.0% | -12.8% |
| 4 | TTM 2025-03-31 | $57.4B | $4.2B | $2.34 | 1.8% | -1.9% | -2.5% |
| 5 | Average | 0.6% | -17.6% | -17.9% |
EPS
Forecasts
Y/Y % Change
ABBV Year-over-Year Growth
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 3.3% | -6.4% | 3.7% | 8.0% | 9.6% | 3.6% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 8 | 8 | |
| EPS Growth (%) | 2.5% | -58.9% | -12.0% | 343.3% | 34.3% | 61.8% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 8 | 8 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $56.2B | $8.9B | $8.0B | $12.3B | $8.5B |
| 2022 | $58.1B | $8.9B | $6.5B | $15.3B | $8.5B |
| 2023 | $54.3B | $11.7B | $7.7B | $12.9B | $8.7B |
| 2024 | $56.3B | $8.5B | $12.8B | $14.8B | $8.4B |
| TTM | $58.3B | $8.7B | $13.1B | $14.6B | $8.3B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 3.30 | 0.25 | -19.09 | 23.57 | -0.63 |
| 2023 | -6.44 | 30.96 | 17.90 | -15.65 | 2.73 |
| 2024 | 3.71 | -27.30 | 66.66 | 14.61 | -3.59 |
| TTM | 3.54 | 1.97 | 2.43 | -0.99 | -1.38 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2025-11-10 08:17 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
| Year | Immunology Rev | Immunology OI | Neuroscience Rev | Neuroscience OI | Hematologic Oncology Rev | Hematologic Oncology OI | Aesthetics Rev | Aesthetics OI | Other Key Products Rev | Other Key Products OI | Eye Care Rev | Eye Care OI | Total Rev | Total OI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | 57.8B | 0.00B | 13.1B | 0.00B | 12B | 0.00B | 10.7B | 0.00B | 6.43B | 0.00B | 5.40B | 0.00B | 105.4B | 0.00B |
| 2023 | 52.3B | 0.00B | 15.4B | 0.00B | 10.9B | 0.00B | 10.6B | 0.00B | 6.34B | 0.00B | 4.83B | 0.00B | 100.3B | 0.00B |
| 2024 | 53.4B | 0.00B | 18B | 0.00B | 12.1B | 0.00B | 10.4B | 0.00B | 5.91B | 0.00B | 4.48B | 0.00B | 104.2B | 0.00B |
| TTM | 53.4B | 0.00B | 18B | 0.00B | 12.1B | 0.00B | 10.4B | 0.00B | 5.91B | 0.00B | 4.48B | 0.00B | 104.2B | 0.00B |
| % of Total (TTM) | 51.2% | — | 17.3% | — | 11.6% | — | 9.9% | — | 5.7% | — | 4.3% | — | 100% | — |
SEGMENTS v2025-09-09 · 2025-11-10 08:17 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue and operating income for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
| Year | S K Y R I Z I Rev | S K Y R I Z I OI | R I N V O Q Rev | R I N V O Q OI | Other Products Rev | Other Products OI | Qulipta Rev | Qulipta OI | Botox Therapeutic Rev | Botox Therapeutic OI | Vyalev Rev | Vyalev OI | Vraylar Rev | Vraylar OI | Ubrelvy Rev | Ubrelvy OI | Elahere Rev | Elahere OI | V E N C L E X T A Rev | V E N C L E X T A OI | Linzess Constella Rev | Linzess Constella OI | Creon Rev | Creon OI | Epkinly Rev | Epkinly OI | Other Oncology Rev | Other Oncology OI | Other Eye Care Rev | Other Eye Care OI | Other Aesthetics Rev | Other Aesthetics OI | Ozurdex Rev | Ozurdex OI | M A V Y R E T Rev | M A V Y R E T OI | Lumigan Ganfort Rev | Lumigan Ganfort OI | Other Neuroscience Rev | Other Neuroscience OI | Alphagan Combigan Rev | Alphagan Combigan OI | Duodopa Rev | Duodopa OI | Juvederm Collection Rev | Juvederm Collection OI | Botox Cosmetic Rev | Botox Cosmetic OI | Imbruvica Rev | Imbruvica OI | H U M I R A Rev | H U M I R A OI | Total Rev | Total OI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | – | – | – | – | 4.14B | 0.00B | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4.14B | 0.00B |
| 2023 | – | – | – | – | 3.04B | 0.00B | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3.04B | 0.00B |
| 2024 | – | – | – | – | 3.03B | 0.00B | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3.03B | 0.00B |
| TTM | 12.2B | 0.00B | 4.73B | 0.00B | 2.70B | 0.00B | 1.39B | 0.00B | 1.01B | 0.00B | 0.71B | 0.00B | 0.63B | 0.00B | 0.63B | 0.00B | 0.42B | 0.00B | 0.41B | 0.00B | 0.21B | 0.00B | 0.16B | 0.00B | 0.16B | 0.00B | 0.02B | 0.00B | -0.01B | 0.00B | -0.02B | 0.00B | -0.02B | 0.00B | -0.03B | 0.00B | -0.05B | 0.00B | -0.07B | 0.00B | -0.08B | 0.00B | -0.13B | 0.00B | -0.32B | 0.00B | -0.36B | 0.00B | -0.78B | 0.00B | -18.5B | 0.00B | 4.99B | 0.00B |
| % of Total (TTM) | 245.3% | — | 94.7% | — | 54.0% | — | 27.8% | — | 20.3% | — | 14.2% | — | 12.6% | — | 12.6% | — | 8.3% | — | 8.1% | — | 4.1% | — | 3.2% | — | 3.2% | — | 0.5% | — | -0.3% | — | -0.4% | — | -0.4% | — | -0.7% | — | -0.9% | — | -1.3% | — | -1.7% | — | -2.6% | — | -6.4% | — | -7.3% | — | -15.6% | — | -371.5% | — | 100% | — |
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $137,182M |
| 1 | Cash | $6,467M |
| 2 | Total Liabilities | $137,320M |
| 3 | Total Debt | $70,481M |
| 4 | Total Equity | $-183M |
| 5 | Debt to Equity Ratio | -385.14 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $185.30 | 4.4% | Nicks Growth: N/A Nick's Expected Margin: N/A FINVIZ Growth: 15% |
Nicks: 6 Finviz: 28 |
Nick's: 0.000 | 5.7 | 79.5 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $2.34 EPS | TTM | $14.96 | -91.9% | $65.52 | -64.6% |
| $12.28 EPS | 2025 | $78.51 | -57.6% | $343.84 | 85.6% |
| $14.06 EPS | 2026 | $89.89 | -51.5% | $393.68 | 112.5% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 29.96% | 9.77% | 30.13% | 9.86% | 2.06% | 0.69% | 36.63% | 10.19% | 100.0% | 69.4% |
| 3 Years | 29.96% | 9.77% | 30.13% | 9.86% | 2.06% | 0.69% | 36.63% | 10.19% | 100.0% | 69.4% |
| 5 Years | 29.96% | 9.77% | 30.13% | 9.86% | 2.06% | 0.69% | 36.63% | 10.19% | 100.0% | 69.4% |
| 10 Years | 29.96% | 9.77% | 30.13% | 9.86% | 2.06% | 0.69% | 36.63% | 10.19% | 100.0% | 69.4% |